{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ACTOS%2Fpioglitazone&page=11",
    "query": {
      "intervention": "ACTOS/pioglitazone",
      "page": 11
    },
    "page_size": 10
  },
  "pagination": {
    "page": 11,
    "page_size": 10,
    "total_count": 258,
    "total_pages": 26,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ACTOS%2Fpioglitazone&page=12&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=ACTOS%2Fpioglitazone&page=10&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T22:53:51.925Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02787551",
      "title": "Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Insulin glargine/lixisenatide fixed ratio combination",
          "type": "DRUG"
        },
        {
          "name": "liraglutide",
          "type": "DRUG"
        },
        {
          "name": "exenatide",
          "type": "DRUG"
        },
        {
          "name": "exenatide extended-release",
          "type": "DRUG"
        },
        {
          "name": "albiglutide",
          "type": "DRUG"
        },
        {
          "name": "dulaglutide",
          "type": "DRUG"
        },
        {
          "name": "Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 514,
      "start_date": "2016-07-06",
      "completion_date": "2018-11-17",
      "has_results": true,
      "last_update_posted_date": "2022-03-25",
      "last_synced_at": "2026-10-17T22:53:51.925Z",
      "location_count": 74,
      "location_summary": "Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fountain Hills",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02787551"
    },
    {
      "nct_id": "NCT01183013",
      "title": "30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Pioglitazone 15 mg",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone 45 mg",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone 30 mg",
          "type": "DRUG"
        },
        {
          "name": "Linagliptin 5mg / Pioglitazone 45 mg FDC",
          "type": "DRUG"
        },
        {
          "name": "Linagliptin 5mg / Pioglitazone 30 mg FDC",
          "type": "DRUG"
        },
        {
          "name": "Linagliptin 5mg",
          "type": "DRUG"
        },
        {
          "name": "Linagliptin 5mg / Pioglitazone 15 mg FDC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 936,
      "start_date": "2010-08",
      "completion_date": "2013-02",
      "has_results": true,
      "last_update_posted_date": "2014-10-20",
      "last_synced_at": "2026-10-17T22:53:51.925Z",
      "location_count": 74,
      "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Muscle Shoals, Alabama + 60 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Muscle Shoals",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01183013"
    },
    {
      "nct_id": "NCT00286494",
      "title": "Study of Alogliptin Combined With Pioglitazone in Subjects With Type 2 Diabetes Mellitus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Alogliptin and pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 493,
      "start_date": "2006-02",
      "completion_date": "2007-08",
      "has_results": true,
      "last_update_posted_date": "2012-02-03",
      "last_synced_at": "2026-10-17T22:53:51.925Z",
      "location_count": 64,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 61 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Artesia",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00286494"
    },
    {
      "nct_id": "NCT00787644",
      "title": "Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Vermont",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 28,
      "start_date": "2009-01",
      "completion_date": "2013-12",
      "has_results": true,
      "last_update_posted_date": "2015-02-26",
      "last_synced_at": "2026-10-17T22:53:51.925Z",
      "location_count": 1,
      "location_summary": "Colchester, Vermont",
      "locations": [
        {
          "city": "Colchester",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00787644"
    },
    {
      "nct_id": "NCT05107765",
      "title": "Effects of Pioglitazone on Stress Reactivity and Alcohol Craving",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Use Disorder"
      ],
      "interventions": [
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center, Houston",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 67,
      "start_date": "2022-05-12",
      "completion_date": "2024-08-16",
      "has_results": true,
      "last_update_posted_date": "2025-08-27",
      "last_synced_at": "2026-10-17T22:53:51.925Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05107765"
    },
    {
      "nct_id": "NCT01023620",
      "title": "HIV Acquired Lipodystrophy (HAL) Classification, Measurement and Fat Response to Thiazolidinedione (TZD) (Pioglitazone)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Observation",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 4,
      "start_date": "2009-10",
      "completion_date": "2010-05-31",
      "has_results": true,
      "last_update_posted_date": "2019-10-08",
      "last_synced_at": "2026-10-17T22:53:51.925Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01023620"
    },
    {
      "nct_id": "NCT00229684",
      "title": "ARMOR (Analyzing Renal Mechanisms of Creatinine Excretion in Patients On tesaglitazaR)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Tesaglitazar",
          "type": "DRUG"
        },
        {
          "name": "pioglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2004-09",
      "completion_date": "2006-06",
      "has_results": false,
      "last_update_posted_date": "2011-08-30",
      "last_synced_at": "2026-10-17T22:53:51.925Z",
      "location_count": 21,
      "location_summary": "Pasadena, California • Washington D.C., District of Columbia • Gainesville, Florida + 18 more",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00229684"
    },
    {
      "nct_id": "NCT01157975",
      "title": "Study the Relationship Between Obesity and Hepatitis C Replication",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2008-10",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2019-12-02",
      "last_synced_at": "2026-10-17T22:53:51.925Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01157975"
    },
    {
      "nct_id": "NCT02535832",
      "title": "Skeletal Muscle Dysfunction in Rheumatoid Arthritis (RA)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis",
        "Insulin Resistance"
      ],
      "interventions": [
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "35 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2015-09",
      "completion_date": "2022-10",
      "has_results": false,
      "last_update_posted_date": "2023-03-27",
      "last_synced_at": "2026-10-17T22:53:51.925Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02535832"
    },
    {
      "nct_id": "NCT07056699",
      "title": "SGLT2i, Pioglitazone, and Ketone Production in T1D",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type1diabetes"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin 10mg Tab",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone 15 MG and 30mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2026-07-01",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-10-17T22:53:51.925Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07056699"
    }
  ]
}